SMHGF (Simcere Pharmaceutical Group) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMHGF Simcere Pharmaceutical Group Ltd SMHGF
94 GF Score
Price $1.49
GF Value $1.26
View Full Analysis

What is Simcere Pharmaceutical Group Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

SMHGF
94GF Score
Simcere Pharmaceutical Group Ltd SMHGF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.49 is trading 18.2% above its estimated GF Value™ of $1.26.

Key valuation signals for SMHGF:

  • Interest Received:
  • GF Value™: $1.26 vs. price of $1.49 (18.2% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for SMHGF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$1.26
GF Value